Re: Annual Financial Reporting

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

fuzzyjr

Rank: Vice President [?]

Points: 5268 [?]

Votes: 36 Score: 3.1 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Annual Financial Reporting

in response to

Re: Annual Financial Reporting

KOO-KOO2

posted on Mar 22, 2024 05:43PM

Well I'm counting on one of the many big pharmas etc working with Zenith to act far quicker than waiting on phase 3's to complete years down the road.

Pfizer along with others are hot on various future cancer pipelines etc etc so that's "my hope" in the near term. Hepa has nothing to do with Zenith & Zenith has everything to do with RVX & im betting on that connection for the greatest benifit to all.